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Several case-control studies have shown associations between the risk of different cancers
and self-reported opium use. Inquiring into relatively sensitive issues, such as the history of
drug use, is usually prone to information bias. However, in order to justify the findings of
these types of studies, we have to quantify the level of such a negative bias. In current
study, we aimed to evaluate sensitivity of self-reported opioid use and suggest suitable
types of control groups for case-control studies on opioid use and the risk of cancer.
Methods
In order to compare the validity of the self-reported opioid use, we cross-validated the
response of two groups of subjects 1) 178 hospitalized patients and 2) 186 healthy individu-
als with the results of their tests using urine rapid drug screen (URDS) and thin layer chro-
matography (TLC). The questioners were asked by trained interviewers to maximize the
validity of responses; healthy individuals were selected from the companions of patients in
hospitals.
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Results
Self-reported regular opioid use was 36.5% in hospitalized patients 19.3% in healthy individ-
uals (p-value> 0.001).The reported frequencies of opioid use in the past 72 hours were
21.4% and 11.8% in hospitalized patients and healthy individuals respectively. Comparing
their responses with the results of urine tests showed a sensitivity of 77% and 69% among
hospitalized patients and healthy individuals for self-reports (p-value = 0.4). Having cor-
rected based on the mentioned sensitivities; the frequency of opioid regular use was 47%
and 28% in hospitalized patients and healthy individuals, respectively. Regular opioid use
among hospitalized patients was significantly higher than in healthy individuals (p-value>
0.001).
Conclusion
Our findings showed that the level of opioid use under-reporting in hospitalized patients and
healthy individuals was considerable but comparable. In addition, the frequency of regular
opioid use among hospitalized patients was significantly higher than that in the general pop-
ulation. Altogether, it seems that, without corrections for these differences and biases, the
results of many studies including case-control studies on opioid use might distort findings
substantially.
Introduction
Self-report bias is a major source of error on the estimates of illegal drugs use or other sensitive
issues. About 30 to 70 percent of persons with positive urine test results refuse reporting illicit
drug use; however, the magnitude of self-report bias depends on the study population [1]. In
conducting case-control studies, we should bear in mind that hospitalized patients as a control
may be more collaborative than healthy individuals, and they tend to report more on their
drug use patterns, leading to less self-report bias [2, 3].
Control selection is an essential issue in case-control studies. The inclusion and exclusion
criteria for control selection need to be explicit. In order to select hospitalized patients as con-
trols in case-control studies, they should be free from the disease of interest and their current
disease should be unrelated to the exposure of interest [4, 5]. Some studies have shown that
hospitalized patients are similar in some of their exposures, and selecting them as controls
could bias results towards the null hypothesis [6].
The exposure frequency in controls should be representative of the study population that
cases come from [7]. Although population-based controls are one of the choices in the design
of a case-control study, it is not feasible in all situations. When studying the association
between cancer and opioid use, which is an illegal behavior, population-based controls may
underreport their exposure history compared to the cancer patients, leading to differential
misclassification and overestimation of the disease-exposure association. According to Abnet
etal. study[8], self-reported opioid use is common in the rural and urban populations of Gole-
stan province, located in northeastern region of Iran. Population-based controls are reliable,
but in order to find the best control and examine the validity in different populations, more
studies are recommended.
In studies comparing drug use self-report with urine analyses, the specificity of drug use
self-report was above 90% and the sensitivity varied from 40% to 75% [9]. Therefore, we
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assume that false positives for drug use self-report are rare and our concern is mostly for false
negatives. This study aimed to estimate sensitivity of self-reported opioid use for the past 72
hours and suggest optimal control groups for conducting case-control studies on opioid use as
their main exposure. Our results will be useful in conducting case-control studies to evaluate
the association between opioid use and the risk of cancer.
Methods
The study population
The current study was a cross-sectional study of an ongoing large multicenter case-control
study investigating associations between opium use and the risk of different cancers. We
selected study subjects from the same four provinces where our case-control study will be con-
ducted, namely Kerman and Fars in the southern region, Golestan in the northeastern region,
and Tehran, the capital city of Iran, because the prevalence of opium use is high in these
provinces.
We compared 178 hospitalized patients and 186 healthy individuals (companions of
patients in hospitals) in terms of opioid use self-report sensitivity for the past 72 hours. Only
men were included, as opium use is rare among women [10, 11]. We tried to include partici-
pants aged from 30 and 75 years old, to accommodate evidence of self-reporting bias for an
older population which is usually recruited in case-control studies on cancer. We excluded
people with a history of cancer.
Hospitalized patients group. We selected study hospitals and wards using purposive
sampling. Hospitals were referral centers for our cancer patients in each province. We selected
hospitalized patients with a diagnosis not related to our study’s main exposure of interest (i.e.
opium use) and our study hospitals were the main treatment centers for them, so they had
approximately similar referral pattern to our cancer patients. We recruited both chronic and
acute patients to resemble our hospitalized patients more closely to cancer patients. Then, we
selected our study hospitalized patients using stratified random sampling according to a five-
year age interval and residential location (living in or outside of the capital city of the prov-
ince). We excluded potential hospitalized patients that were too ill to answer the
questionnaire.
Healthy individuals group. Healthy individuals were the companions of chronic disease
patients in the same hospitals where our hospitalized patients were recruited. We recruited
healthy individuals with a sampling method similar to hospitalized patients.
Questionnaire and data collection
We confirmed the face and content validity of the questionnaire through several expert opin-
ion meetings. We examined the test-retest reliability of the questionnaire on a convenience
sample of 50 addicts who were referred to an addiction treatment center on two occasions
separated by a two week-interval. All reliability indices were above 0.7. The questionnaire
included questions on opioid use [12] including raw opium [13], Shireh (the condensed
extract of remnants of smoked opium)[12] and Sukhteh (the remnants of smoked opium) [14]
considered together as opium, and also heroin, Crack of heroin (a heroin-based narcotic used
in Iran which is different from the cocaine-based crack used in Western countries) [15], and
non-medical morphine, as well as the history of use of other substances, including alcohol and
tobacco (cigarettes and hookah). Moreover, it included questions on demographic characteris-
tics, socioeconomic status, job title, diseases, and use of medicines, including drugs containing
codeine and morphine during the last two weeks, to differentiate medical opioid use from ille-
gal opioid use.
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For hospitalized patients, we recorded the date of their first symptom and disease onset and
also their pain status (severe, moderate, or mild) according to their self-reports. Regular sub-
stance use was defined as consumption at least once a week for at least a six month period dur-
ing the subject’s lifetime. Also, we asked participants about the date of their last opioid use to
compare their self-reports with urine test results. Although participants were aware of the
study hypothesis, they were not aware of these specific hypotheses unless they inquired during
the process of obtaining informed consent.
Interviewers with a Bachelor of Arts degree in psychology or social work were specially
trained for this study in a two-day workshop to standardize the interviewing process and miti-
gate inter-rater variability. A detailed questionnaire guideline was used. All the participants
were invited for interview in private rooms. We introduced the study to participants; for peo-
ple who refused to participate, we collected information on age, education level, marital status,
and the reasons for refusal using a query form called the refusal form. After the interview, we
collected urine samples for laboratory analyses.
Laboratory tests
In this study, we used two types of urine drug screens tests, urine rapid drug screen (URDS)
and immunoassay thin layer chromatography (TLC). The URDS test is one of the most com-
mon methods for the initial screening procedure [16]. TLC uses antibodies to detect metabo-
lites or the presence of specific drugs and is considered the gold standard for confirmatory
testing. The method can detect small amounts of a substance and is the most sensitive, accu-
rate, and reliable method of testing; conversely, the test is time-consuming, a high level of
expertise is required to perform it, and it is costly. Consequently, TLC is usually done only
after a positive result is obtained in the URDS test [16].
For the initial screening, we used the URDS test to assess the presence of opioid metabolites,
including morphine (cutoff point: 300 ng/ml). The test protocol was provided by the toxicol-
ogy laboratory of Iranian National Center for Addiction Studies (INCAS). Metabolites of mor-
phine are detectable in the urine, at the utmost, for 72 hours after use. Consequently, TLC tests
were used for participants with a positive URDS test result, but who denied opioid use in the
questionnaire, either regular use or during the past 72 hours. [17].
Statistical analyses
We performed descriptive analysis using mean and proportions for quantitative and qualita-
tive variables. We then used chi-squared tests and t-tests to compare the two groups with
respect to demographic variables. In order to adjust for the clustering effect of conducting a
multicenter study, we performed multilevel logistic regression analysesbut the result was not
significantly different from the simple analysis. Therefore, we present the simple analysis
results for easier interpretation (S1 and S2 Tables).
We used information on the use of morphine in the past 72 hours and the results of the
urine tests. TLC was considered as the gold standard. We compared the sensitivity of self-
reported opioid use in the past 72 hours in both groups. As opioid metabolites are detectable
in the urine for 72 hours, to calculate the sensitivity, the numerator was the number of partici-
pants who consumed opioids during the past 72 hours based on their self-reports, and the
denominator was the number of people who consumed opioids in the past 72 hours (sum of
self-report and TLC test result).
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Study power
We used a sample size calculation formula for comparing the two proportions. Assuming a
15% difference between proportions, a type one error (α) of 5%, and a design effect of 1.5,
about 170 subjects were needed in each group to evaluate the sensitivity of the questionnaire
for the evaluation of opioid use with 80% power.
Ethical considerations
The ethics committee of Tehran University of Medical Sciences approved the study (Ethical
code: 27867–142022). All participants provided written informed consent. The data of the par-
ticipants were handled confidentially. Urine samples were kept anonymous for investigators
and the results were not linked to participants’ identities in the dataset. Participants received a
small gift after interview.
Results
Participant characteristics
Healthy individuals and hospitalized patients were not significantly different regarding the dis-
tribution of their demographic characteristics (Table 1). Participation rates were high in both
healthy individuals (86%) and hospitalized patients (88%). Non-participants were defined as
people who refused to participate after study introduction. About half of the non-participation
rates were due to unwillingness to provide urine samples in both groups.
Table 1. Comparison of healthy individuals and hospitalized patients according to demographic variables and self-reported regular substance
use.
Healthy Individuals (n = 186) Hospitalized Patients
(n = 178)
P-value
Mean (SD) Mean (SD)
Age 53.2 (11.8) 53.1 (12.2) 0.9
Number (%) Number (%)
Education
 High school 153 (82.3) 157 (88.2) 0.1
> High school 33 (17.7) 21 (11.8)
Marital status*
Single 11 (6) 13 (7.3) 0.6
Married 17 5(94) 165 (92.7)
History of regular substance use
Opioid use** 36 (19.3) 65 (36.5) 0.001***
Opium (raw opium, Shireh and Sukhteh) 35 (18.8) 64 (36) 0.001***
Crack of heroin 1(0.5) 2 (1.1) 0.5
Heroin 3 (1.6) 1 (0.6) 0.3
Morphine (without prescription) 0 1 (0.6) 0.3
Alcohol use 25 (13.4) 30 (16.8) 0.4
Cigarette use 82 (44.1) 80 (45.2) 0.8
Hookah use 1 3(7) 8 (4.5) 0.3
*Frequency of widowed and divorced people were low, so we considered them as single.
** Opioid use refers to use of raw opium, Shireh (the condensed extract of remnants of smoked opium), Sukhteh (remnants of smoked opium), Crack of
heroin (crystalized form of heroin), and morphine (without prescription).
*** significant at the 0.05 level
https://doi.org/10.1371/journal.pone.0183017.t001
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The median duration of disease in hospitalized patients was 5.5 months (interquartile
range: 0.01–3 years). Hospitalized patients were recruited in different wards, including ortho-
pedics (17.4%), endocrinology (16.9%), surgery, (13%), neurology (10%), urology (10%), and
other wards (32.7%) including ear, nose & throat, internal medicine, gastroenterology, neuro-
surgery, infectious, and eye disease wards. Most of the participants had no (43.3%) or mild
(27%) pain.
Prevalence of self-reported opioid use
Self-reported regular opioid use was significantly lower in healthy individuals (19.3%) than
hospitalized patients (36.5%) (Table 2). Out of the 186 healthy individuals, 36 reported regular
opioid use. Among the 36 healthy individuals who were regular opioid users, 22 (61.1%)
reported opioid use during the past 72 hours. Out of 65 hospitalized patients who were regular
users of opioids, 38 (57.6%) reported using opioids during the past 72 hours (Fig 1). In addi-
tion, about 10 percent of regular opioid users in the hospitalized patients started opioid con-
sumption after the onset of their disease according to their self-reports.
Sensitivity of self-reported opioid use
Among the 36 healthy individuals who reported regular opioid use, the URDS test was positive
in 25 (69.4%). Out of the 37 healthy individuals with a positive morphine URDS test result, 16
(43.2%) did not report regular or past 72 hours opioid use during the interview. TLC was posi-
tive in 10 of this group (Fig 1).
The URDS for morphine test results were positive for 45 (69%) and negative for 20 (31%)
of patients who reported regular opioid use. According to the URDS test results, 22 hospital-
ized patients did not report opioid use regularly or in the past 72 hours during the interview.
We performed the TLC test for these patients. The TLC test result was positive for 11 (50%) of
them (Fig 1).
We compared two groups in terms of the sensitivity of their self-reported opioid use during
the past 72 hours. According to the URDS and TLC test results, the sensitivity of self-reported
opioid use during the past 72 hours was 77% (CI: 65.8% -89.2%) in the hospitalized patients
and 69% (CI: 52.8% -84.9%) in the healthy individuals (Table 2).
Table 2. Comparison of healthy individuals and hospitalized patients in terms of opioid use based on self-report and TLC test results.
Subject healthy individuals hospitalized patients P-value
N* n* (%) N* n* (%)
1. Regular opioid use (at least once a week for at least a six month period during the
subject’s lifetime) based on self-report**
186 36 (19.3) 178 65 (36.5) >0.001***
2. consumed opioids during the past 72 hours based on self-report 186 22 (11.8) 178 38 (21.4) 0.01***
3. Positive TLC test results among those who denied opioid use during the past 72
hours
164 10 (6.1) 140 11 (7.9) 0.7
4. Consumed opioids in the past 72 hours (sum of rows 2 and 3) 186 32 (17.2) 178 49 (27.5) 0.02***
5. Sensitivity of self-report in those who consumed opioids during the past 72 hours 32 22 (68.8) 49 38 (77.5) 0.4
* The denominator for the calculation of each row was not the same; we show denominator for each row with the letter N and the numerator with the letter n.
** Opioid use refers to regular use of raw opium, Shireh (the condensed extract of remnants of smoked opium), Sukhteh (remnants of smoked opium),
Crack of heroin (crystalized form of heroin), and morphine (without prescription).
*** Significant at the 0.05 level.
https://doi.org/10.1371/journal.pone.0183017.t002
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Prevalence based on TLC results
In order to estimate the true prevalence of self-reported regular opioid use, we divided this
value by the sensitivity of self-reported opioid use within the past 72 hours. True prevalence of
regular opioid use according to the sensitivity was estimated to be 28% (CI: 21.6–35) and
47.4% (CI: 39.7–54.8) for healthy individuals and hospitalized patients, respectively. This was
significantly lower in healthy individuals than in hospitalized patients (P-value0.001).
Discussion
We conducted a cross-sectional study to measure the sensitivity of self-reported opioid during
the past 72 hours use among healthy individuals and hospitalized patients in a case-control
study. Regular opioid use was significantly more frequent in hospitalized patients than in
healthy individuals, even after correcting for underreporting. However, hospitalized patients
and healthy individuals did not differ in terms of assessing the sensitivity of opioid use in the
past 72 hours, non-participation rates, and reasons for non-participation.
The prevalence of regular opioid use in hospitalized patients was significantly higher than
in other studies [18] and to what is estimated to be the prevalence of regular opioid use in the
general population in Iran, namely 15–20% [19, 20]. This may be because opioids are some-
times used as a pain reliever among hospitalized patients, or because long-term opioid use
may cause disease. Previous studies have reported statistically significant positive associations
between opium use and a higher risk of some of common diseases, such as cardiovascular dis-
ease [21, 22], cancer [23], and all-cause mortality[24]. Despite our strict inclusion and exclu-
sion criteria for the selection of hospitalized patients, we cannot rule out that the cause of
hospitalization among hospitalized patients was not related to opioid use. Bias by indication
could have occurred, as the patients who had chronic disease could use opioids to mitigate
pain and discomfort before hospital admission.
The prevalence of regular opioid use in healthy individuals was lower than the hospitalized
patients, and closer to the estimated prevalence of regular opioid uses in general population
[19, 20]. On the other hand, the sensitivity of assessing opioid use in the past 72 hours was sim-
ilar in both groups; thus, the lower prevalence of regular opioid use in healthy individuals is
less likely due to an underreporting bias.
Previous studies have shown that substance use is more prevalent in people younger than
50 years of age [10]. In this study, we considered the same age distribution for both groups;
Fig 1. Flowchart of study participation, self-reported opioid use and urine test results in healthy
individuals and hospitalized patients.
https://doi.org/10.1371/journal.pone.0183017.g001
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thus, the differences between healthy individuals and hospitalized patients cannot be attribut-
able to their age distribution differences. Substance use has been reported to be less prevalent
among married people and in people with a higher educational level [10]. However, we found
no statistically significant difference in marital status or educational level between the two
groups.
Moreover, there were no significant differences in participation rates between the two
groups in our study. However according to other studies, healthy individuals usually have a
lower participation rate [25] and underreport their substance use, as a result of feeling insecure
[3, 26]. The high participation rates in our study could be due to the fact that we recruited sub-
jects in hospitals, and because we used well-trained interviewers who were strictly supervised.
According to the current study results, healthy individuals are superior to hospitalized
patients as control for conducting case-control study. This is consistent with a study by Shakeri
et al [18] on the association between the risk of squamous cell carcinoma of the esophagus and
opium use. According to this study, neighborhood controls were superior to hospitalized
patients as their prevalence of opium use was more similar to the general population. However,
according to our study results, underreporting in both groups was not ignorable and studies
on sensitive issues like opium use should be careful about false negative results and correct
their estimations for this bias, which could lead to finding a spurious association.
Strengths and limitations
Cross-validating self-reported opioid use within the past 72 hours with urine test results is
strength of the current study. This is the first study in Iran to compare urine test results with
self-reported opioid use in the past 72 hours instead of regular opioid use. Moreover, we used
well-trained interviewers under strict supervision, resulting in a high participation rate. One of
the limitations of the current study was the impossibility of calculating the negative predictive
value of self-reported opioid use in the past 72 hours, because TLC tests were too expensive
and it was not possible to use them for all participants.
Conclusions
In conclusion, by gaining the trust of healthy individuals, we observed a comparable self-
reporting bias to that of hospitalized patients. The prevalence of self-reported regular opioid
use among healthy individuals was similar to the general population. Therefore, recruiting
healthy individuals as controls in a trustworthy setting like a hospital could be more suitable in
conducting case-control studies on the use of substances like opioids. Clearly, without correc-
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